Novel strategies for the treatment of grass pollen-induced allergic rhinitis
(2016) In Expert Opinion on Biological Therapy 16(9). p.1143-1150- Abstract
Introduction: Allergic rhinitis (AR) affects over 20% of the population of Europe and the United States. Allergen immunotherapy (AIT) is currently the only form of treatment that affects symptoms and modifies the progression of disease. Established forms of AIT include subcutaneous (SCIT) and sublingual (SLIT) immunotherapy and are widely effective, yet only 2-9% of eligible patients undergo therapy, likely due to the long duration of treatment. As a result, novel, faster forms of AIT are currently under development. Areas covered: This article provides an overview of AR and summarises the efficacy and mechanisms of established forms of AIT, highlighting the current drawbacks. We discuss novel strategies of AIT that have been developed... (More)
Introduction: Allergic rhinitis (AR) affects over 20% of the population of Europe and the United States. Allergen immunotherapy (AIT) is currently the only form of treatment that affects symptoms and modifies the progression of disease. Established forms of AIT include subcutaneous (SCIT) and sublingual (SLIT) immunotherapy and are widely effective, yet only 2-9% of eligible patients undergo therapy, likely due to the long duration of treatment. As a result, novel, faster forms of AIT are currently under development. Areas covered: This article provides an overview of AR and summarises the efficacy and mechanisms of established forms of AIT, highlighting the current drawbacks. We discuss novel strategies of AIT that have been developed in an attempt to tackle these limitations, including epicutaneous, intradermal and intralymphatic immunotherapy (ILIT), focusing on ILIT, the treatment that has been most comprehensively assessed. Expert opinion: Current strategies to treat AR suffer from a poor safety profile and, importantly, lack of adherence. ILIT is a faster and safer form of AIT, with a treatment regime of only 12 weeks. Further validation is required, but ILIT, with its short and comparatively inexpensive protocol, has the potential to offer disease-modifying therapy to a larger number of patients.
(Less)
- author
- Larsson, Olivia ; Hellkvist, Laila ; Peterson-Westin, Ulla LU and Cardell, Lars Olaf LU
- organization
- publishing date
- 2016-09-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- allergen immunotherapy, Allergic rhinitis, allergy, grass pollen, intralymphatic immunotherapy
- in
- Expert Opinion on Biological Therapy
- volume
- 16
- issue
- 9
- pages
- 8 pages
- publisher
- Taylor & Francis
- external identifiers
-
- scopus:84981743093
- pmid:27269991
- wos:000382346100008
- ISSN
- 1471-2598
- DOI
- 10.1080/14712598.2016.1190829
- language
- English
- LU publication?
- yes
- id
- 5e525094-0a45-4e80-b99c-b2f0b8a3c734
- date added to LUP
- 2016-11-11 15:50:05
- date last changed
- 2025-01-12 15:01:52
@article{5e525094-0a45-4e80-b99c-b2f0b8a3c734,
abstract = {{<p>Introduction: Allergic rhinitis (AR) affects over 20% of the population of Europe and the United States. Allergen immunotherapy (AIT) is currently the only form of treatment that affects symptoms and modifies the progression of disease. Established forms of AIT include subcutaneous (SCIT) and sublingual (SLIT) immunotherapy and are widely effective, yet only 2-9% of eligible patients undergo therapy, likely due to the long duration of treatment. As a result, novel, faster forms of AIT are currently under development. Areas covered: This article provides an overview of AR and summarises the efficacy and mechanisms of established forms of AIT, highlighting the current drawbacks. We discuss novel strategies of AIT that have been developed in an attempt to tackle these limitations, including epicutaneous, intradermal and intralymphatic immunotherapy (ILIT), focusing on ILIT, the treatment that has been most comprehensively assessed. Expert opinion: Current strategies to treat AR suffer from a poor safety profile and, importantly, lack of adherence. ILIT is a faster and safer form of AIT, with a treatment regime of only 12 weeks. Further validation is required, but ILIT, with its short and comparatively inexpensive protocol, has the potential to offer disease-modifying therapy to a larger number of patients.</p>}},
author = {{Larsson, Olivia and Hellkvist, Laila and Peterson-Westin, Ulla and Cardell, Lars Olaf}},
issn = {{1471-2598}},
keywords = {{allergen immunotherapy; Allergic rhinitis; allergy; grass pollen; intralymphatic immunotherapy}},
language = {{eng}},
month = {{09}},
number = {{9}},
pages = {{1143--1150}},
publisher = {{Taylor & Francis}},
series = {{Expert Opinion on Biological Therapy}},
title = {{Novel strategies for the treatment of grass pollen-induced allergic rhinitis}},
url = {{http://dx.doi.org/10.1080/14712598.2016.1190829}},
doi = {{10.1080/14712598.2016.1190829}},
volume = {{16}},
year = {{2016}},
}